{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:06:25Z","timestamp":1795046785512,"version":"4.10.2"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A systematic review and Bayesian network meta-analysis is necessary to evaluate the efficacy and safety of triple therapy with different doses of inhaled corticosteroids (ICS) in stable chronic obstructive pulmonary disease (COPD). We selected 26 parallel randomized controlled trials (41,366 patients) comparing triple therapy with ICS\/long-acting beta-agonist (LABA), LABA\/long-acting muscarinic antagonist (LAMA), and LAMA in patients with stable COPD for\u2009\u2265\u200912\u00a0weeks from PubMed, EMBASE, the Cochrane Library, and clinical trial registries (search from inception to June 30, 2022). Triple therapy with high dose (HD)-ICS exhibited a lower risk of total exacerbation in pre-specified subgroups treated for\u2009\u2265\u200948\u00a0weeks than that with low dose (LD)-ICS (odds ratio [OR]\u2009=\u20090.66, 95% credible interval [CrI]\u2009=\u20090.52\u20130.94, low certainty of evidence) or medium dose (MD)-ICS (OR\u2009=\u20090.66, 95% CrI\u2009=\u20090.51\u20130.94, low certainty of evidence). Triple therapy with HD-ICS exhibited a lower risk of moderate-to-severe exacerbation in pre-specified subgroups with forced expiratory volume in 1\u00a0s\u2009&lt;\u200965% (OR\u2009=\u20090.6, 95% CrI\u2009=\u20090.37\u20130.98, low certainty of evidence) or previous exacerbation history (OR\u2009=\u20090.6, 95% CrI\u2009=\u20090.36\u20130.999, very low certainty of evidence) than triple therapy with MD-ICS. Triple therapy with HD-ICS may reduce acute exacerbation in patients with COPD treated with other drug classes including triple therapy with LD- or MD-ICS or dual therapies.<\/jats:p>","DOI":"10.1038\/s41598-022-18353-y","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:03:36Z","timestamp":1663679016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Hyun Woo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Moon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"18353_CR1","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1056\/nejm199906243402503","volume":"340","author":"RA Pauwels","year":"1999","unstructured":"Pauwels, R. A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 340, 1948\u20131953. https:\/\/doi.org\/10.1056\/nejm199906243402503 (1999).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR2","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","volume":"320","author":"PS Burge","year":"2000","unstructured":"Burge, P. S. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ (Clin. Res. Ed.) 320, 1297\u20131303. https:\/\/doi.org\/10.1136\/bmj.320.7245.1297 (2000).","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"18353_CR3","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1056\/nejm200012283432601","volume":"343","author":"R Wise","year":"2000","unstructured":"Wise, R., Connett, J., Weinmann, G., Scanlon, P. & Skeans, M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 1902\u20131909. https:\/\/doi.org\/10.1056\/nejm200012283432601 (2000).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa041892","volume":"352","author":"K Ito","year":"2005","unstructured":"Ito, K. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967\u20131976. https:\/\/doi.org\/10.1056\/NEJMoa041892 (2005).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/s0140-6736(03)12459-2","volume":"361","author":"P Calverley","year":"2003","unstructured":"Calverley, P. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 361, 449\u2013456. https:\/\/doi.org\/10.1016\/s0140-6736(03)12459-2 (2003).","journal-title":"Lancet"},{"key":"18353_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775\u2013789. https:\/\/doi.org\/10.1056\/NEJMoa063070 (2007).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR7","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","volume":"201","author":"DA Lipson","year":"2020","unstructured":"Lipson, D. A. et al. Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 201, 1508\u20131516. https:\/\/doi.org\/10.1164\/rccm.201911-2207OC (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"FJ Martinez","year":"2021","unstructured":"Martinez, F. J. et al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am. J. Respir. Crit. Care Med. 203, 553\u2013564. https:\/\/doi.org\/10.1164\/rccm.202006-2618OC (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR9","doi-asserted-by":"publisher","first-page":"e1002958","DOI":"10.1371\/journal.pmed.1002958","volume":"16","author":"HW Lee","year":"2019","unstructured":"Lee, H. W., Park, J., Jo, J., Jang, E. J. & Lee, C. H. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. PLoS Med. 16, e1002958. https:\/\/doi.org\/10.1371\/journal.pmed.1002958 (2019).","journal-title":"PLoS Med."},{"key":"18353_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1183\/09031936.00193908","volume":"34","author":"C Crim","year":"2009","unstructured":"Crim, C. et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 34, 641\u2013647. https:\/\/doi.org\/10.1183\/09031936.00193908 (2009).","journal-title":"Eur. Respir. J."},{"key":"18353_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/resp.12127","volume":"18","author":"CH Lee","year":"2013","unstructured":"Lee, C. H. et al. Risk of hospital admission or emergency room visit for pneumonia in patients using respiratory inhalers: A case-crossover study. Respirology 18, 1116\u20131127. https:\/\/doi.org\/10.1111\/resp.12127 (2013).","journal-title":"Respirology"},{"key":"18353_CR12","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2008.717","volume":"300","author":"MB Drummond","year":"2008","unstructured":"Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J. & Fan, E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 300, 2407\u20132416. https:\/\/doi.org\/10.1001\/jama.2008.717 (2008).","journal-title":"JAMA"},{"key":"18353_CR13","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.2147\/copd.S175047","volume":"13","author":"JL Izquierdo","year":"2018","unstructured":"Izquierdo, J. L. & Cosio, B. G. The dose of inhaled corticosteroids in patients with COPD: When less is better. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 3539\u20133547. https:\/\/doi.org\/10.2147\/copd.S175047 (2018).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"18353_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1183\/09031936.04.00076604","volume":"23","author":"M Masoli","year":"2004","unstructured":"Masoli, M., Holt, S., Weatherall, M. & Beasley, R. Dose-response relationship of inhaled budesonide in adult asthma: A meta-analysis. Eur. Respir. J. 23, 552\u2013558. https:\/\/doi.org\/10.1183\/09031936.04.00076604 (2004).","journal-title":"Eur. Respir. J."},{"key":"18353_CR15","first-page":"16","volume":"59","author":"M Masoli","year":"2004","unstructured":"Masoli, M., Weatherall, M., Holt, S. & Beasley, R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 59, 16\u201320 (2004).","journal-title":"Thorax"},{"key":"18353_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04233-2020","author":"P Rogliani","year":"2021","unstructured":"Rogliani, P., Ritondo, B. L. & Calzetta, L. Triple therapy in uncontrolled asthma: A network meta-analysis of phase III studies. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.04233-2020 (2021).","journal-title":"Eur. Respir. J."},{"key":"18353_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe, K. F. et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N. Engl. J. Med. 383, 35\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1916046 (2020).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","volume":"146","author":"SD Aaron","year":"2007","unstructured":"Aaron, S. D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann. Intern. Med. 146, 545\u2013555. https:\/\/doi.org\/10.7326\/0003-4819-146-8-200704170-00152 (2007).","journal-title":"Ann. Intern. Med."},{"key":"18353_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.pupt.2006.06.001","volume":"20","author":"M Cazzola","year":"2007","unstructured":"Cazzola, M. et al. A pilot study to assess the effects of combining fluticasone propionate\/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. 20, 556\u2013561. https:\/\/doi.org\/10.1016\/j.pupt.2006.06.001 (2007).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"18353_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen, H. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 371, 1285\u20131294. https:\/\/doi.org\/10.1056\/NEJMoa1407154 (2014).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/thoraxjnl-2014-206670","volume":"70","author":"PA Frith","year":"2015","unstructured":"Frith, P. A. et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol\/fluticasone in patients with COPD: The GLISTEN study, a randomised controlled trial. Thorax 70, 519\u2013527. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206670 (2015).","journal-title":"Thorax"},{"key":"18353_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","volume":"198","author":"KR Chapman","year":"2018","unstructured":"Chapman, K. R. et al. Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): A randomized, double-blind, triple-dummy clinical trial. Am. J. Respir. Crit. Care Med. 198, 329\u2013339. https:\/\/doi.org\/10.1164\/rccm.201803-0405OC (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR23","unstructured":"Register, E. C. T. A multinational, multicentre, randomised, open-label, active-controlled, 26-week, 2-arm, parallel group study to evaluate the non-inferiority of fixed combination of beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide administered via pMDI (CHF 5993) versus fixed combination of fluticasone furoate plus vilanterol administered via DPI (Relvar\u00ae) plus tiotropium bromide (Spiriva\u00ae) for the treatment of patients with chronic obstructive pulmonary disease. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001487-35\/results (Accessed 30 June 2021)."},{"key":"18353_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12931-020-01360-w","volume":"21","author":"GT Ferguson","year":"2020","unstructured":"Ferguson, G. T. et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: Lung function and health status results from two replicate randomized controlled trials. Respir. Res. 21, 131. https:\/\/doi.org\/10.1186\/s12931-020-01360-w (2020).","journal-title":"Respir. Res."},{"key":"18353_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","volume":"180","author":"T Welte","year":"2009","unstructured":"Welte, T. et al. Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180, 741\u2013750. https:\/\/doi.org\/10.1164\/rccm.200904-0492OC (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2011.09.002","volume":"106","author":"NA Hanania","year":"2012","unstructured":"Hanania, N. A. et al. Benefits of adding fluticasone propionate\/salmeterol to tiotropium in moderate to severe COPD. Respir. Med. 106, 91\u2013101. https:\/\/doi.org\/10.1016\/j.rmed.2011.09.002 (2012).","journal-title":"Respir. Med."},{"key":"18353_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.rmed.2011.09.004","volume":"106","author":"KS Jung","year":"2012","unstructured":"Jung, K. S. et al. Comparison of tiotropium plus fluticasone propionate\/salmeterol with tiotropium in COPD: A randomized controlled study. Respir. Med. 106, 382\u2013389. https:\/\/doi.org\/10.1016\/j.rmed.2011.09.004 (2012).","journal-title":"Respir. Med."},{"key":"18353_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/resp.12646","volume":"21","author":"SD Lee","year":"2016","unstructured":"Lee, S. D. et al. Efficacy and tolerability of budesonide\/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. Respirology 21, 119\u2013127. https:\/\/doi.org\/10.1111\/resp.12646 (2016).","journal-title":"Respirology"},{"key":"18353_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15412555.2015.1034256","volume":"13","author":"TM Siler","year":"2016","unstructured":"Siler, T. M., Kerwin, E., Singletary, K., Brooks, J. & Church, A. Efficacy and safety of umeclidinium added to fluticasone propionate\/salmeterol in patients with COPD: Results of two randomized, double-blind studies. COPD 13, 1\u201310. https:\/\/doi.org\/10.3109\/15412555.2015.1034256 (2016).","journal-title":"COPD"},{"key":"18353_CR30","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/s0140-6736(16)31354-x","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh, D. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial. Lancet 388, 963\u2013973. https:\/\/doi.org\/10.1016\/s0140-6736(16)31354-x (2016).","journal-title":"Lancet"},{"key":"18353_CR31","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/s0140-6736(17)30188-5","volume":"389","author":"J Vestbo","year":"2017","unstructured":"Vestbo, J. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial. Lancet 389, 1919\u20131929. https:\/\/doi.org\/10.1016\/s0140-6736(17)30188-5 (2017).","journal-title":"Lancet"},{"key":"18353_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson, G. T. et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 6, 747\u2013758. https:\/\/doi.org\/10.1016\/s2213-2600(18)30327-8 (2018).","journal-title":"Lancet Respir. Med."},{"key":"18353_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/s0140-6736(18)30206-x","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi, A. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial. Lancet 391, 1076\u20131084. https:\/\/doi.org\/10.1016\/s0140-6736(18)30206-x (2018).","journal-title":"Lancet"},{"key":"18353_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12931-021-01683-2","volume":"22","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: The TRIVERSYTI randomised controlled trial. Respir. Res. 22, 90. https:\/\/doi.org\/10.1186\/s12931-021-01683-2 (2021).","journal-title":"Respir. Res."},{"key":"18353_CR35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.rmed.2015.06.006","volume":"109","author":"TM Siler","year":"2015","unstructured":"Siler, T. M. et al. Efficacy and safety of umeclidinium added to fluticasone furoate\/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir. Med. 109, 1155\u20131163. https:\/\/doi.org\/10.1016\/j.rmed.2015.06.006 (2015).","journal-title":"Respir. Med."},{"key":"18353_CR36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson, D. A. et al. FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 196, 438\u2013446. https:\/\/doi.org\/10.1164\/rccm.201703-0449OC (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR37","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson, D. A. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 378, 1671\u20131680. https:\/\/doi.org\/10.1056\/NEJMoa1713901 (2018).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR38","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.3892\/etm.2018.6773","volume":"16","author":"D Zhao","year":"2018","unstructured":"Zhao, D., Ling, C., Guo, Q., Jin, J. & Xu, H. Efficacy and safety of tiotropium bromide combined with budesonide\/formoterol in the treatment of moderate to severe chronic obstructive pulmonary disease. Exp. Ther. Med. 16, 4578\u20134584. https:\/\/doi.org\/10.3892\/etm.2018.6773 (2018).","journal-title":"Exp. Ther. Med."},{"key":"18353_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41533-021-00241-z","volume":"31","author":"S Bansal","year":"2021","unstructured":"Bansal, S. et al. Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy versus tiotropium monotherapy in patients with COPD. NPJ Prim. Care Respir. Med. 31, 29. https:\/\/doi.org\/10.1038\/s41533-021-00241-z (2021).","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"18353_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung, K. F. et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43, 343\u2013373. https:\/\/doi.org\/10.1183\/09031936.00202013 (2014).","journal-title":"Eur. Respir. J."},{"key":"18353_CR41","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1056\/NEJMra1608969","volume":"377","author":"E Israel","year":"2017","unstructured":"Israel, E. & Reddel, H. K. Severe and difficult-to-treat asthma in adults. N. Engl. J. Med. 377, 965\u2013976. https:\/\/doi.org\/10.1056\/NEJMra1608969 (2017).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/all.13760","volume":"74","author":"PJ Barnes","year":"2019","unstructured":"Barnes, P. J. Inflammatory endotypes in COPD. Allergy 74, 1249\u20131256. https:\/\/doi.org\/10.1111\/all.13760 (2019).","journal-title":"Allergy"},{"key":"18353_CR43","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/mi.2015.12","volume":"8","author":"L Dejager","year":"2015","unstructured":"Dejager, L. et al. Neutralizing TNF\u03b1 restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol. 8, 1212\u20131225. https:\/\/doi.org\/10.1038\/mi.2015.12 (2015).","journal-title":"Mucosal Immunol."},{"key":"18353_CR44","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1038\/s41598-022-09241-6","volume":"12","author":"J Milara","year":"2022","unstructured":"Milara, J. et al. The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro. Sci. Rep. 12, 5132. https:\/\/doi.org\/10.1038\/s41598-022-09241-6 (2022).","journal-title":"Sci. Rep."},{"key":"18353_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/thx.2003.019349","volume":"59","author":"RA O'Donnell","year":"2004","unstructured":"O\u2019Donnell, R. A. et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 59, 837\u2013842. https:\/\/doi.org\/10.1136\/thx.2003.019349 (2004).","journal-title":"Thorax"},{"key":"18353_CR46","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMoa032158","volume":"350","author":"JC Hogg","year":"2004","unstructured":"Hogg, J. C. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 2645\u20132653. https:\/\/doi.org\/10.1056\/NEJMoa032158 (2004).","journal-title":"N. Engl. J. Med."},{"key":"18353_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1164\/rccm.200505-704OC","volume":"173","author":"JR Hurst","year":"2006","unstructured":"Hurst, J. R., Perera, W. R., Wilkinson, T. M., Donaldson, G. C. & Wedzicha, J. A. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173, 71\u201378. https:\/\/doi.org\/10.1164\/rccm.200505-704OC (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR48","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.rmed.2005.04.025","volume":"99","author":"D Ozol","year":"2005","unstructured":"Ozol, D. et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir. Med. 99, 1494\u20131500. https:\/\/doi.org\/10.1016\/j.rmed.2005.04.025 (2005).","journal-title":"Respir. Med."},{"key":"18353_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2015.11.004","volume":"36","author":"M Cazzola","year":"2016","unstructured":"Cazzola, M. et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm. Pharmacol. Ther. 36, 1\u20139. https:\/\/doi.org\/10.1016\/j.pupt.2015.11.004 (2016).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"18353_CR50","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3389\/fphar.2018.01426","volume":"9","author":"M Yamada","year":"2018","unstructured":"Yamada, M. & Ichinose, M. The cholinergic pathways in inflammation: A potential pharmacotherapeutic target for COPD. Front. Pharmacol. 9, 1426. https:\/\/doi.org\/10.3389\/fphar.2018.01426 (2018).","journal-title":"Front. Pharmacol."},{"key":"18353_CR51","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.2174\/138161206778194187","volume":"12","author":"A Miller-Larsson","year":"2006","unstructured":"Miller-Larsson, A. & Selroos, O. Advances in asthma and COPD treatment: Combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr. Pharm. Des. 12, 3261\u20133279. https:\/\/doi.org\/10.2174\/138161206778194187 (2006).","journal-title":"Curr. Pharm. Des."},{"key":"18353_CR52","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1111\/bph.13628","volume":"173","author":"R Newton","year":"2016","unstructured":"Newton, R. & Giembycz, M. A. Understanding how long-acting \u03b2(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma\u2014An update. Br. J. Pharmacol. 173, 3405\u20133430. https:\/\/doi.org\/10.1111\/bph.13628 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"18353_CR53","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/bph.14909","volume":"177","author":"P Rogliani","year":"2020","unstructured":"Rogliani, P. et al. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. Br. J. Pharmacol. 177, 1150\u20131163. https:\/\/doi.org\/10.1111\/bph.14909 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"18353_CR54","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1183\/09031936.00133805","volume":"28","author":"DD Sin","year":"2006","unstructured":"Sin, D. D., Anthonisen, N. R., Soriano, J. B. & Agusti, A. G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 28, 1245\u20131257. https:\/\/doi.org\/10.1183\/09031936.00133805 (2006).","journal-title":"Eur. Respir. J."},{"key":"18353_CR55","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1183\/09031936.00095909","volume":"35","author":"YK Loke","year":"2010","unstructured":"Loke, Y. K., Kwok, C. S. & Singh, S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur. Respir. J. 35, 1003\u20131021. https:\/\/doi.org\/10.1183\/09031936.00095909 (2010).","journal-title":"Eur. Respir. J."},{"key":"18353_CR56","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(16)30069-1","volume":"387","author":"J Vestbo","year":"2016","unstructured":"Vestbo, J. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet 387, 1817\u20131826. https:\/\/doi.org\/10.1016\/s0140-6736(16)30069-1 (2016).","journal-title":"Lancet"},{"key":"18353_CR57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","volume":"178","author":"BR Celli","year":"2008","unstructured":"Celli, B. R. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am. J. Respir. Crit. Care Med. 178, 332\u2013338. https:\/\/doi.org\/10.1164\/rccm.200712-1869OC (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR58","doi-asserted-by":"publisher","first-page":"k4388","DOI":"10.1136\/bmj.k4388","volume":"363","author":"Y Zheng","year":"2018","unstructured":"Zheng, Y. et al. Triple therapy in the management of chronic obstructive pulmonary disease: Systematic review and meta-analysis. BMJ 363, k4388. https:\/\/doi.org\/10.1136\/bmj.k4388 (2018).","journal-title":"BMJ"},{"key":"18353_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1164\/rccm.200611-1630OC","volume":"176","author":"P Ernst","year":"2007","unstructured":"Ernst, P., Gonzalez, A. V., Brassard, P. & Suissa, S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med. 176, 162\u2013166. https:\/\/doi.org\/10.1164\/rccm.200611-1630OC (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR60","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1164\/rccm.201007-1099OC","volume":"183","author":"P Brassard","year":"2011","unstructured":"Brassard, P., Suissa, S., Kezouh, A. & Ernst, P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am. J. Respir. Crit. Care Med. 183, 675\u2013678. https:\/\/doi.org\/10.1164\/rccm.201007-1099OC (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"18353_CR61","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.amjmed.2010.06.019","volume":"123","author":"S Suissa","year":"2010","unstructured":"Suissa, S., Kezouh, A. & Ernst, P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 123, 1001\u20131006. https:\/\/doi.org\/10.1016\/j.amjmed.2010.06.019 (2010).","journal-title":"Am. J. Med."},{"key":"18353_CR62","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/thx.2011.160028","volume":"66","author":"YK Loke","year":"2011","unstructured":"Loke, Y. K., Cavallazzi, R. & Singh, S. Risk of fractures with inhaled corticosteroids in COPD: Systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66, 699\u2013708. https:\/\/doi.org\/10.1136\/thx.2011.160028 (2011).","journal-title":"Thorax"},{"key":"18353_CR63","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1136\/bjo.87.10.1247","volume":"87","author":"L Smeeth","year":"2003","unstructured":"Smeeth, L., Boulis, M., Hubbard, R. & Fletcher, A. E. A population based case-control study of cataract and inhaled corticosteroids. Br. J. Ophthalmol. 87, 1247\u20131251. https:\/\/doi.org\/10.1136\/bjo.87.10.1247 (2003).","journal-title":"Br. J. Ophthalmol."},{"key":"18353_CR64","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s2213-2600(14)70169-9","volume":"2","author":"L Finney","year":"2014","unstructured":"Finney, L. et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir. Med. 2, 919\u2013932. https:\/\/doi.org\/10.1016\/s2213-2600(14)70169-9 (2014).","journal-title":"Lancet Respir. Med."},{"key":"18353_CR65","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1586\/14737167.2.4.367","volume":"2","author":"AJ Sutton","year":"2002","unstructured":"Sutton, A. J. et al. Meta-analysis of rare and adverse event data. Expert Rev. Pharmacoecon. Outcomes Res. 2, 367\u2013379. https:\/\/doi.org\/10.1586\/14737167.2.4.367 (2002).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"18353_CR66","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","volume":"11","author":"JP Jansen","year":"2008","unstructured":"Jansen, J. P., Crawford, B., Bergman, G. & Stam, W. Bayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons. Value Health 11, 956\u2013964. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00347.x (2008).","journal-title":"Value Health"},{"key":"18353_CR67","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01219-2018","author":"A Agusti","year":"2018","unstructured":"Agusti, A. et al. Inhaled corticosteroids in COPD: Friend or foe?. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.01219-2018 (2018).","journal-title":"Eur. Respir. J."},{"key":"18353_CR68","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 162, 777\u2013784. https:\/\/doi.org\/10.7326\/m14-2385 (2015).","journal-title":"Ann. Intern. Med."},{"key":"18353_CR69","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 18, e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583 (2021).","journal-title":"PLoS Med."},{"key":"18353_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta4380","volume":"4","author":"DJ Spiegelhalter","year":"2000","unstructured":"Spiegelhalter, D. J., Myles, J. P., Jones, D. R. & Abrams, K. R. Bayesian methods in health technology assessment: A review. Health Technol. Assess. 4, 1\u2013130 (2000).","journal-title":"Health Technol. Assess."},{"key":"18353_CR71","unstructured":"Global Strategy for Asthma Management and Prevention. Global Strategy for Asthma Management and Prevention, http:\/\/www.ginasthma.org (2022)."},{"key":"18353_CR72","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan, J. et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J. Clin. Epidemiol. 75, 40\u201346. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021 (2016).","journal-title":"J. Clin. Epidemiol."},{"key":"18353_CR73","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/2046-4053-3-151","volume":"3","author":"Z Liu","year":"2014","unstructured":"Liu, Z., Rich, B. & Hanley, J. A. Recovering the raw data behind a non-parametric survival curve. Syst. Rev. 3, 151. https:\/\/doi.org\/10.1186\/2046-4053-3-151 (2014).","journal-title":"Syst. Rev."},{"key":"18353_CR74","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1183\/09031936.00110913","volume":"43","author":"AJ Mackay","year":"2014","unstructured":"Mackay, A. J. et al. Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur. Respir. J. 43, 735\u2013744. https:\/\/doi.org\/10.1183\/09031936.00110913 (2014).","journal-title":"Eur. Respir. J."},{"key":"18353_CR75","doi-asserted-by":"publisher","first-page":"46s","DOI":"10.1183\/09031936.03.00078002","volume":"41","author":"S Burge","year":"2003","unstructured":"Burge, S. & Wedzicha, J. A. COPD exacerbations: Definitions and classifications. Eur. Respir. J. Suppl. 41, 46s\u201353s. https:\/\/doi.org\/10.1183\/09031936.03.00078002 (2003).","journal-title":"Eur. Respir. J. Suppl."},{"key":"18353_CR76","unstructured":"Health, U. D. o. & Services, H. (2018)."},{"key":"18353_CR77","unstructured":"Program, N. C. I. C. T. E. Common Terminology Criteria for Adverse Events:(CTCAE). (Cancer Therapy Evaluation Program, 2003)."},{"key":"18353_CR78","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898. https:\/\/doi.org\/10.1136\/bmj.l4898 (2019).","journal-title":"BMJ"},{"key":"18353_CR79","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, d5928. https:\/\/doi.org\/10.1136\/bmj.d5928 (2011).","journal-title":"BMJ"},{"key":"18353_CR80","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu, G. & Ades, A. E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23, 3105\u20133124. https:\/\/doi.org\/10.1002\/sim.1875 (2004).","journal-title":"Stat. Med."},{"key":"18353_CR81","unstructured":"Dias, S., Welton, N. J., Sutton, A. J. & Ades, A. E. In NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials (National Institute for Health and Care Excellence (NICE) Copyright \u00a9 2014 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved., 2014)."},{"key":"18353_CR82","unstructured":"Carlin, B. P., Hong, H., Shamliyan, T. A., Sainfort, F. & Kane, R. L. In Case Study Comparing Bayesian and Frequentist Approaches for Multiple Treatment Comparisons (Agency for Healthcare Research and Quality (US), 2013)."},{"key":"18353_CR83","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1159\/000515133","volume":"100","author":"HW Lee","year":"2021","unstructured":"Lee, H. W., Kim, H. J., Jang, E. J. & Lee, C. H. Comparisons of efficacy and safety between triple (inhaled corticosteroid\/long-acting muscarinic antagonist\/long-acting beta-agonist) therapies in chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. Respir. Int. Rev. Thorac. Dis. 100, 631\u2013643. https:\/\/doi.org\/10.1159\/000515133 (2021).","journal-title":"Respir. Int. Rev. Thorac. Dis."},{"key":"18353_CR84","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias, S., Welton, N. J., Caldwell, D. M. & Ades, A. E. Checking consistency in mixed treatment comparison meta-analysis. Stat. Med. 29, 932\u2013944. https:\/\/doi.org\/10.1002\/sim.3767 (2010).","journal-title":"Stat. Med."},{"key":"18353_CR85","doi-asserted-by":"crossref","unstructured":"Spiegelhalter, D. J., Abrams, K. R. & Myles, J. P. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Vol. 13 (Wiley, 2004).","DOI":"10.1002\/0470092602"},{"key":"18353_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc9182","volume":"14","author":"JL Moran","year":"2010","unstructured":"Moran, J. L., Graham, P. L., Rockliff, S. & Bersten, A. D. J. C. C. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: A Bayesian meta-analytic perspective. Crit. Care 14, 1\u201315 (2010).","journal-title":"Crit. Care"},{"key":"18353_CR87","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti, G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool. Res. Synth. Methods 3, 80\u201397 (2012).","journal-title":"Res. Synth. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18353-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18353-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18353-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:28:09Z","timestamp":1663680489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18353-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18353"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18353-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"29 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author (C.H.L.) received a research fund, which is not related to this manuscript, from GSK. Other authors have completed the ICMJE uniform disclosure form at  and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3\u00a0years; no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15698"}}